Jin Hee Kim, Paul Rafla, Jaclyn Wang, Aliya Zuberi, Ruoqi Wei, Ryan Murr, Karen Spindler, Meghan Hungate, Carlo Felizardo, Michael Dziuban, Matt Donnelly, Kate Long, Jason Zhang
February 23, 2026
Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics
1 min
AI-made summary
- • Gibson Dunn represented BioCryst Pharmaceuticals, Inc
- in securing a $400 million senior secured term loan facility
- • The loan facility was used to finance BioCryst's acquisition of Astria Therapeutics, Inc
- • The Gibson Dunn team included specialists in finance, licensing, intellectual property, FDA and regulatory matters, and tax aspects
- • Key team members included partner Jin Hee Kim, with additional partners and associates advising on various legal aspects of the transaction.
Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc.~~The Gibson Dunn finance team involved in the transaction was led by partner Jin Hee Kim and included associates Paul Rafla, Jaclyn Wang, Aliya Zuberi, and Ruoqi Wei. Partners Ryan Murr, Karen Spindler, and Meghan Hungate advised on licensing and intellectual property. Of counsel Carlo Felizardo and associate Michael Dziuban advised on FDA and regulatory matters. Partner Matt Donnelly, of counsel Kate Long, and associate Jason Zhang advised on tax aspects.~~Download PDF~~
Article Author
Jin Hee Kim, Paul Rafla, Jaclyn Wang, Aliya Zuberi, Ruoqi Wei, Ryan Murr, Karen Spindler, Meghan Hungate, Carlo Felizardo, Michael Dziuban, Matt Donnelly, Kate Long, Jason Zhang
The Sponsor